Clovis Oncology Appoints Dr. Lindsey Rolfe as Chief Medical Officer

Dr. Rolfe, currently Clovis' Senior Vice President of Clinical Development, oversees the rociletinib and rucaparib development programs

Dr. Andrew Allen stepping down after rociletinib NDA/MAA submissions to create a new biotech company and serve as its CEO

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that Dr. Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, has been named Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance, to become effective in early August. Dr. Rolfe succeeds Dr. Andrew Allen, who will be stepping down from his role at Clovis at that time to create a new immuno-oncology focused biotechnology company and serve as its Chief Executive Officer (CEO). Dr. Rolfe joined Clovis in early 2010 and oversees rociletinib and rucaparib development in her current role as Senior Vice President of Clinical Development.

"I've loved working with Andrew at Clovis, and before that at our prior company, but I always knew this day would come and that Andrew would eventually pursue his interest in starting and running his own company"

"I've loved working with Andrew at Clovis, and before that at our prior company, but I always knew this day would come and that Andrew would eventually pursue his interest in starting and running his own company," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "The submissions of the NDA and MAA for rociletinib planned in July represent a final accomplishment for his tenure with Clovis and a clean transition point for our organization. I wish him the very best, and am confident he will do a great job in his new venture."

Mr. Mahaffy added: "I am also delighted that Lindsey will now serve as our Chief Medical Officer. Lindsey has been an integral part of the Clovis team and has done a superb job leading the rociletinib and rucaparib clinical development programs. She is well prepared for this role, and will provide a seamless transition both internally and externally with our clinical investigators. I am confident that she will continue to successfully execute on our development programs, as well as be very effective in her expanded responsibilities."

Prior to her appointment as Executive VP and Chief Medical Officer, Dr. Rolfe served as Senior Vice President of Clinical Development at Clovis. Dr. Rolfe previously served in senior oncology development roles at Celgene Corporation, Pharmion Corporation, Cambridge Antibody Technology, UCB Inc. and Celltech Group plc. She has specialist accreditation in pharmaceutical medicine.

As Chief Medical Officer at Clovis, Dr. Rolfe will be responsible for clinical development, preclinical development, clinical operations and pharmacovigilance and will also serve on the Company's executive committee. She will be based in the Company's San Francisco office.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado.

To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in our clinical development programs for our drug candidates, the corresponding development pathways of our companion diagnostics, actions by the FDA, the EMA or other regulatory authorities regarding whether to approve drug applications that may be filed, as well as their decisions regarding drug labeling, and other matters that could affect the availability or commercial potential of our drug candidates or companion diagnostics, including competitive developments. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.

Contacts
Clovis Oncology, Inc.
Anna Sussman, 303-625-5022
[email protected]
Breanna Burkart, 303-625-5023
[email protected]

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.